Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 107 clinical trials
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and

myelofibrosis
cell transplantation
  • 0 views
  • 11 Jul, 2022
  • 19 locations
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how safe and tolerable ABBV-744 is, when given alone, and in combination with ruxolitinib or

  • 22 views
  • 28 Jul, 2022
  • 34 locations
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

previously treated with ruxolitinib. The primary objective of the study is to evaluate the percentage of subjects with at least 35% spleen volume reduction in the fedratinib and the BAT arms.

anemia
thrombocytosis
fedratinib
ruxolitinib
cancer
  • 161 views
  • 12 Jul, 2022
  • 107 locations
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

-HLF, or BCL2/MYC or with Down syndrome, by comparing event-free survival to historical control from TOTXVI. To determine the tolerability of combination therapy with ruxolitinib and Early

residual tumor
daunorubicin
vincristine
blinatumomab
cyclophosphamide
  • 278 views
  • 11 May, 2022
  • 7 locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or …

platelet count
blood blast count
direct bilirubin
ejection fraction
polycythemia
  • 698 views
  • 23 Apr, 2022
  • 74 locations
Ruxolitinib for Cancer Cachexia

To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in

  • 0 views
  • 14 May, 2022
  • 1 location
Ruxolitinib for Premalignant Breast Disease (TBCRC042)

This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive

carcinoma in situ
atypical ductal hyperplasia
breast disease
lobular carcinoma in situ
breast biopsy
  • 49 views
  • 23 May, 2022
  • 7 locations
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

this study is: Ruxolitinib

busulfan
leukemia
hla-a
granulocyte colony stimulating factor
colony stimulating factor
  • 36 views
  • 30 Jan, 2022
  • 6 locations
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with

nivolumab
measurable disease
graft versus host disease
classical hodgkin lymphoma
chemotherapy regimen
  • 39 views
  • 21 Mar, 2022
  • 3 locations
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

With Ruxolitinib. The experiment is divided into two parts: dose exploration and extended research.

anemia
platelet count
thrombocytosis
essential thrombocythemia
colony stimulating factor
  • 22 views
  • 24 Jun, 2021
  • 1 location